BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Klingberg S, Herrlich J, Wiedemann G, Wölwer W, Meisner C, Engel C, Jakobi-Malterre UE, Buchkremer G, Wittorf A. Adverse effects of cognitive behavioral therapy and cognitive remediation in schizophrenia: results of the treatment of negative symptoms study. J Nerv Ment Dis. 2012;200:569-576. [PMID: 22759932 DOI: 10.1097/nmd.0b013e31825bfa1d] [Cited by in Crossref: 33] [Cited by in F6Publishing: 6] [Article Influence: 3.7] [Reference Citation Analysis]
Number Citing Articles
1 Naeem F, Gire N, Xiang S, Yang M, Syed Y, Shokraneh F, Adams C, Farooq S. Reporting and understanding the safety and adverse effect profile of mobile apps for psychosocial interventions: An update. World J Psychiatry 2016;6:187-91. [PMID: 27354959 DOI: 10.5498/wjp.v6.i2.187] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 5] [Article Influence: 2.4] [Reference Citation Analysis]
2 Polese D, Fornaro M, Palermo M, De Luca V, de Bartolomeis A. Treatment-Resistant to Antipsychotics: A Resistance to Everything? Front Psychiatry. 2019;10:210. [PMID: 31057434 DOI: 10.3389/fpsyt.2019.00210] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
3 Jones C, Hacker D, Meaden A, Cormac I, Irving CB, Xia J, Zhao S, Shi C, Chen J. Cognitive behavioural therapy plus standard care versus standard care plus other psychosocial treatments for people with schizophrenia. Cochrane Database Syst Rev 2018;11:CD008712. [PMID: 30480760 DOI: 10.1002/14651858.CD008712.pub3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
4 Pyle M, Norrie J, Schwannauer M, Kingdon D, Gumley A, Turkington D, Byrne R, Syrett S, MacLennan G, Dudley R, McLeod HJ, Griffiths H, Bowe S, Barnes TR, French P, Hutton P, Davies L, Morrison AP. Design and protocol for the Focusing on Clozapine Unresponsive Symptoms (FOCUS) trial: a randomised controlled trial. BMC Psychiatry 2016;16:280. [PMID: 27496180 DOI: 10.1186/s12888-016-0983-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 2.4] [Reference Citation Analysis]
5 Bello NT, Yeomans BL. Safety of pharmacotherapy options for bulimia nervosa and binge eating disorder. Expert Opin Drug Saf 2018;17:17-23. [PMID: 29053927 DOI: 10.1080/14740338.2018.1395854] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 3.8] [Reference Citation Analysis]
6 Glenthøj LB, Fagerlund B, Randers L, Hjorthøj CR, Wenneberg C, Krakauer K, Vosgerau A, Gluud C, Medalia A, Roberts DL, Nordentoft M. The FOCUS trial: cognitive remediation plus standard treatment versus standard treatment for patients at ultra-high risk for psychosis: study protocol for a randomised controlled trial. Trials 2015;16:25. [PMID: 25623736 DOI: 10.1186/s13063-014-0542-8] [Cited by in Crossref: 30] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]